explore -WSS

explore

author：comprehensive 2025-09-07 17:20:29 - browse：731

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Liquid biopsy for lung cancer is launched by Delfi

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

Senate panel eyes new effort on drug shortages

Physician executives need more than on

SNAP should offer more nutrition education

A Q&A with the global head of Boehringer Ingelheim's innovation unit

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

entertainment

explore

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Bristol Myers buys into radiopharmaceuticals with RayzeBio

BioMarin wins approval for gene therapy to treat hemophilia A

FDA authorizes Novavax’s updated Covid

Novavax promises a turnaround & Lilly roils the obesity market

SNAP should offer more nutrition education

How to save PrEP access — and even expand it

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

In Memoriam: Notable people who died in 2023

Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Prime Medicine, Myeloid Therapeutics clash over genome

How to keep neuroscience’s past racism from being its future

Analysis of telehealth claims data suggest service duplication

Medicare drug price negotiation hasn't dried up venture capital

Editas, Vertex strike deal on CRISPR

focus

focus

Wikipedia

knowledge